Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab)

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is an uncommon autoinflammatory syndrome, with an estimated prevalence of 1 in 10,000 in the Caucasian population.1 SAPHO is defined by the diagnostic criteria proposed by Kahn et al,2 which includes either a chronic multifocal sterile osteomyelitis, sterile osteitis, or arthritis.1,3 The latter 2 require at least 1 accompanying dermatologic feature, which includes palmoplantar pustulosis, pustular psoriasis, or severe acne.